MercyJuaquin Remora, Gynecology Resident

Physician Referal 1.800.MD-Mercy Mercy Sponsored by the Sisters of Mercy 301 St. Paul Place Baltimore, MD 21202 Phone: 410.332.9000 TTY: 410.332.9888 web: www.MDMercy.com Privacy Policy

Home > Prevention & Research Center > Research Studies

Prevention & Research Center: Research Studies

Mercy’s widely-regarded physicians and clinical team work diligently to provide unparalleled care, beginning with providing the most sophisticated, leading-edge therapies. Physician experts work in tandem with The Prevention & Research Center at Mercy, focusing on translating research into clinical care and bridging breakthrough findings into emerging treatments. Mercy’s specialized research teams are actively involved in innovative clinical trials and research studies which cross multiple medical disciplines and seek to advance the treatment of countless diseases.

Working closely with prestigious national research institutes and health foundations, Mercy’s experts are dedicated to conducting vital research leading to breakthroughs in prevention, diagnosis and treatment.

Current Research Studies

Breast Cancer Trials

Colon & Rectal Cancer Trials

Melanoma Trials

Other Studies

 

Back to Top

 

Breast Cancer Trials

Adverse Effects of Hormone Deprivation Therapy

Sponsor: Susan G. Komen Breast Cancer Foundation
Principal Investigator: Kathy J. Helzlsouer, MD, MHS
Research Nurse: Bethany D. Wood, MHS, 410-951-7958

We are trying to learn more about the side effects of breast cancer
treatments and how we may be able to treat or prevent them. For this
study, we are looking for women who are taking aromatase inhibitors
(Femara, Arimdex, or Aromasin) or who will be taking these medications.
We are also looking for women who do not have a breast cancer. This
study will give us clues for finding ways to decrease the side effects
of treatment. The study is supported in part by the Susan G. Komen
Breast Cancer Foundation.

You may be eligible for this study if you are in menopause and

  • Have had breast cancer
  • Are/will be taking an aromatase inhibitor (Femara, Arimdex, or Aromasin)
OR
  • Have NOT had breast cancer
  • Or any other cancer except skin or early stage cervical cancer

If you are eligible, you will be asked to complete questionnaires, give
blood samples, and have a bone density measurement. In addition, some
participants will be asked to return for a three month and six month
follow up visit. There will be no compensation for being in the study
but you will be given the results of your laboratory tests and bone
density screening at no cost to you. We will also cover the costs of
parking or public transportation.

We are currently recruiting for this study.

To find out more about the study and to see if you are eligible please
call Ms. Bethany Wood at 410-951-7958 or contact us by email at
prc@mdmercy.com.

 

A randomized trial to evaluate a family-focused mind body medicine intervention to reduce fatigue among breast cancer survivors 

Sponsor: American Breast Cancer Foundation
Principal Investigators: Kathy J. Helzlsouer, MD, MHS, Julianne Oktay, MSW, PhD
Research Nurse: Susan Appling, MS, CRNP at 410-951-7952

Many breast cancer survivors continue to fight fatigue months and years after treatment is over. This research study is being done to test the benefits of two different ways to conduct a program to help reduce fatigue among women who have had breast cancer.

A previous study of our standard 10 week group based mind-body medicine program showed that symptoms of fatigue could be improved. We are now trying to find out if this holistic program plus sessions with family members or others who are important in the lives of breast cancer survivors can help reduce fatigue. This program will be compared to the standard program without these additional sessions. 

You may be able to join this study if:

  • You have had breast cancer and it has been at least three months since you finished chemotherapy or radiation therapy (you may still be on hormone therapy)
  • Over the past four weeks you felt worn out or tired at least some of the time
  • Over the past four weeks you felt full of life and energy only some of the time

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer.

Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

 

A Phase 3 Study of SU011248 in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-line Advanced Disease Setting in Patients Having Breast Cancer

Sponsor: Pfizer
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

 

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Sponsor: Southwest Oncology Group
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

This three year study is being done to find how well adding a bisphosphonate to hormonal or chemotherapy will help in preventing future recurrence of breast cancer in bones and other parts of the body. You will be assigned (by a process similar to flipping a coin) to 1 of 3 treatment groups.  Group 1 will get Zoledronic Acid through your vein (IV) monthly for 6 months, then once every 3 months for 2.5 years; Group 2 will take Clodronate daily by mouth for 3 years; and Group 3 will take Ibandronate daily by mouth for 3 years.  Treatment with the study drug can begin prior to, with, or after beginning chemotherapy.  All study drugs will be given free of charge by the pharmaceutical companies. 

 

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment (The TAILORx Breast Trial)

Sponsor: Eastern Cooperative Oncology Group
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

In this trial, the OncotypeDx Breast Cancer Assay will be used to guide treatment decisions in women whose lymph nodes do not contain cancer but whose tumor is either Estrogen Positive and/or Progesterone Positive. This test is done on the tumor tissue and will help to identify women who have a low, intermediate and high risk for developing future recurrence of their breast cancer.  Previous studies have suggested that only women with a high risk of recurrence benefit from getting chemotherapy.  This study is trying to answer the question of whether women with an intermediate risk of recurrence benefit from chemotherapy.  Based on the OncotypeDx test results eligible women will be in one of four groups.  Women with a test result suggesting a low risk of breast cancer recurrence will receive only hormonal treatment (Arm A).  Women who have a test result suggesting a high risk of recurrence will receive chemotherapy and hormonal therapy (Arm D).  Women in the intermediate group will be selected by chance (using a computer program that is similar to flipping a coin) to receive either chemotherapy + hormonal therapy (ARM C) or hormonal therapy alone (ARM B).  Following chemotherapy (if given) women may be given whole breast radiation. 

Back to Top

Colon & Rectal Trials

A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer

Sponsor: Amgen
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

Back to Top

Melanoma Trials

Multi-center Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multi-center Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node

Sponsor: John Wayne Cancer Institute
Principal Investigator: Armando Sardi, M.D., 410-332-9294
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

 

Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma

Sponsor: Vical
Principal Investigator: Armando Sardi, M.D., 410-332-9294
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

Back to Top

 

Other Studies

Mercy Medical Center “Pilot Study" to Demonstrate the Link between H. Pylori and Development of Pseudomyxoma Peritonei (PMP)

Sponsor: Mercy Medical Center
Principal Investigator: Armando Sardi, M.D., 410-332-9294
Research Nurses: Richard Shrout, RN, MSN, 410-332-9459 and Lisa McConnell, RN, BSN, 410-332-1200

Back to Top

.

 

 

 

.
Site Map